404 related articles for article (PubMed ID: 31415916)
1. Irinotecan: 25 years of cancer treatment.
Bailly C
Pharmacol Res; 2019 Oct; 148():104398. PubMed ID: 31415916
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Khageh Hosseini S; Kolterer S; Steiner M; von Manstein V; Gerlach K; Trojan J; Waidmann O; Zeuzem S; Schulze JO; Hahn S; Steinhilber D; Gatterdam V; Tampé R; Biondi RM; Proschak E; Zörnig M
Biochem Pharmacol; 2017 Dec; 146():53-62. PubMed ID: 29031818
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Yao Y; Yu L; Su X; Wang Y; Li W; Wu Y; Cheng X; Zhang H; Wei X; Chen H; Zhang R; Gou L; Chen X; Xie Y; Zhang B; Zhang Y; Yang J; Wei Y
J Control Release; 2015 Dec; 220(Pt A):5-17. PubMed ID: 26439663
[TBL] [Abstract][Full Text] [Related]
6. Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib.
Lu J; Hu Y; Qian R; Zhang Y; Yang X; Luo P
Eur J Pharmacol; 2020 May; 874():173022. PubMed ID: 32084420
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
LaRose M; Connolly RM; O'Sullivan CC; Velcheti V; Vilimas R; Gano K; Bates SE; Pommier Y; Thomas A
Oncologist; 2023 May; 28(5):460-e298. PubMed ID: 37010988
[TBL] [Abstract][Full Text] [Related]
8. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
[TBL] [Abstract][Full Text] [Related]
11. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
13. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience.
Tossey JC; Reardon J; VanDeusen JB; Noonan AM; Porter K; Arango MJ
Med Oncol; 2019 Sep; 36(10):87. PubMed ID: 31494781
[TBL] [Abstract][Full Text] [Related]
14. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
15. The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Martín-Encinas E; Selas A; Palacios F; Alonso C
Expert Opin Drug Discov; 2022 Jun; 17(6):581-601. PubMed ID: 35321631
[TBL] [Abstract][Full Text] [Related]
16. The effects of estrogen on targeted cancer therapy drugs.
Zhao Y; Wang X; Liu Y; Wang HY; Xiang J
Pharmacol Res; 2022 Mar; 177():106131. PubMed ID: 35167895
[TBL] [Abstract][Full Text] [Related]
17. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
[TBL] [Abstract][Full Text] [Related]
20. Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers.
Bailly C
Int Immunopharmacol; 2019 Dec; 77():105967. PubMed ID: 31670091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
